These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35501220)

  • 1. New Antivirals and Immune Therapies for COVID-19 Infection.
    Miro JM; Torres A; Paredes R
    Arch Bronconeumol; 2022 Apr; 58 Suppl 1():8-10. PubMed ID: 35501220
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral antiviral treatments for COVID-19: opportunities and challenges.
    Rahmah L; Abarikwu SO; Arero AG; Essouma M; Jibril AT; Fal A; Flisiak R; Makuku R; Marquez L; Mohamed K; Ndow L; Zarębska-Michaluk D; Rezaei N; Rzymski P
    Pharmacol Rep; 2022 Dec; 74(6):1255-1278. PubMed ID: 35871712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How do we best use Paxlovid and other covid antivirals?
    Lang K
    BMJ; 2023 Aug; 382():1666. PubMed ID: 37586745
    [No Abstract]   [Full Text] [Related]  

  • 4. Embracing Uncertainties Over the Evidence of New Oral Antivirals for COVID-19: Challenges in Pharmacoepidemiologic Research.
    Ferreira da Silva R; Silva AM; Morato M; Ribeiro-Vaz I; Polónia JJ
    J Clin Pharmacol; 2023 May; 63(5):521-525. PubMed ID: 36519976
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral and intravenous 1'-cyano-substituted adenosine-like antivirals for early COVID-19.
    Gottlieb RL; Paredes R
    Lancet Infect Dis; 2024 Feb; 24(2):108-110. PubMed ID: 38006893
    [No Abstract]   [Full Text] [Related]  

  • 6. COVID-19 and the Functionality of Antivirals: The Day After Tomorrow.
    Sharifan A
    Health Secur; 2022; 20(3):270-271. PubMed ID: 35723880
    [No Abstract]   [Full Text] [Related]  

  • 7. Newer oral antivirals for COVID-19: Are they the real game changer?
    Kunal S; Sakthivel P; Malhotra N; Ish P
    Heart Lung; 2022; 52():200-203. PubMed ID: 35078637
    [No Abstract]   [Full Text] [Related]  

  • 8. Future of antivirals in COVID-19: The case of favipiravir.
    Kow CS; Ramachandram DS; Hasan SS
    Int Immunopharmacol; 2022 Feb; 103():108455. PubMed ID: 34959188
    [No Abstract]   [Full Text] [Related]  

  • 9. A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals.
    Chitalia VC; Munawar AH
    J Transl Med; 2020 Oct; 18(1):390. PubMed ID: 33059719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WHO Living Guidelines on antivirals for COVID-19 are evidence-based.
    Owen A; Diaz JV; Guyatt G; Lamontagne F; Stegemann M; Vandvik PO; Agoritsas T
    Lancet; 2022 Dec; 400(10369):2196-2198. PubMed ID: 36372074
    [No Abstract]   [Full Text] [Related]  

  • 11. Coronavirus disease 2019 (COVID-19) oral antivirals stewardship: Establishing game rules.
    Mazonakis N; Tsioutis C; Markaki I; Papadakis M; Papadakos S; Spernovasilis N
    Infect Control Hosp Epidemiol; 2022 Dec; 43(12):1990-1992. PubMed ID: 35115067
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of antivirals on COVID-19: a systematic review.
    Hussain N; Yoganathan A; Hewage S; Alom S; Harky A
    Expert Rev Anti Infect Ther; 2021 Apr; 19(4):473-486. PubMed ID: 32924650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA Oligonucleotides as Antivirals and Vaccine Constituents against SARS Coronaviruses: A Prospective Tool for Immune System Tuning.
    Oberemok VV; Andreeva OA; Alieva EE
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No shortcuts to SARS-CoV-2 antivirals.
    Edwards A; Hartung IV
    Science; 2021 Jul; 373(6554):488-489. PubMed ID: 34326222
    [No Abstract]   [Full Text] [Related]  

  • 15. A practical update on the management of patients with COVID-19.
    Mehta M; Navarra A; Mogal R
    Clin Med (Lond); 2022 Sep; 22(5):468-474. PubMed ID: 36507813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.
    Izzi A; Messina V; Rinaldi L; Maggi P
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5193-5194. PubMed ID: 32495848
    [No Abstract]   [Full Text] [Related]  

  • 17. An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
    McMahon JH; Lau JSY; Roney J; Rogers BA; Trubiano J; Sasadeusz J; Molton JS; Gardiner B; Lee SJ; Hoy JF; Cheng A; Peleg AY
    Trials; 2020 Oct; 21(1):847. PubMed ID: 33050947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical Guide to New Treatments for SARS-CoV-2 Infection in Dermatology Patients Being Treated With Common Immunomodulators.
    Viedma-Martínez M; Gallo-Pineda G; Jiménez-Gallo D
    Actas Dermosifiliogr; 2023 Jan; 114(1):49-53. PubMed ID: 35963337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antivirals for COVID-19 and Breastfeeding.
    Anderson PO
    Breastfeed Med; 2020 Oct; 15(10):605-607. PubMed ID: 32936682
    [No Abstract]   [Full Text] [Related]  

  • 20. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
    Sutanto ST; Sinto R; Pasaribu A; Shakinah S
    Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.